Day: March 9, 2022

Yield10 Bioscience Announces Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 9, 2022. Posted in Earnings Releases And Operating Results.

-Near-term commercial focus on the Renewable Diesel market -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported financial results for the three and twelve months ended December 31, 2021. “In 2021 we executed against our strategic plan to position Camelina as a commercial platform crop for the production of low-carbon petroleum replacements and food products,” said Oliver Peoples, Ph.D., Chief Executive Officer of Yield10 Bioscience. “We made solid progress as we focused on activities to position Yield10 to be able to launch and commercialize Camelina...

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 9, 2022. Posted in Earnings Releases And Operating Results.

LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. “I am exceptionally proud of the Keros team’s performance in 2021, as we advanced all aspects of our business, including securing a strategic partnership with Hansoh for KER-050 in mainland China, Hong Kong and Macau,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “Our momentum is accelerating, as we reported positive initial data from our...

Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress

Written by Customer Service on March 9, 2022. Posted in Earnings Releases And Operating Results.

– Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 – – Phase 2 trial in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) on track to initiate this quarter – – Signed agreement with Ypsomed for development of autoinjector for potential use in PRA023 registrational studies – – Strong cash position of $257.3 million at year-end 2021 – SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported financial...

INNOVATE Corp. Announces Fourth Quarter and Full Year 2021 Results

Written by Customer Service on March 9, 2022. Posted in Earnings Releases And Operating Results.

– Infrastructure: DBM Global delivers record revenue of $383.4 million in the fourth quarter and maintains backlog level primed for a successful 2022 –– Life Sciences: R2 started shipping Glacial Spa to China in preparation for launch –– Spectrum: Broadcasting expands footprint into 12 new designated market areas – NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the fourth quarter and fiscal year ended December 31, 2021. Financial Summary(in millions, except per share amounts) Three Months Ended December 31, Twelve Months Ended December 31, 2021 2020 Increase / (Decrease) 2021 2020 Increase / (Decrease)Revenue $ 394.8 $ 178.0 121.8 % $ 1,205.2 $ 716.9 68.1 %Net...

Antisense Therapeutics to present poster at world’s largest NMD conference

Written by Customer Service on March 9, 2022. Posted in Public Companies.

New York, NY, March 09, 2022 (GLOBE NEWSWIRE) — Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George Tachas, the Company’s Director of Drug Discovery and Patents, will present an e-poster on new data from its Phase II study of ATL1102 in patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder that primarily affects boys. It is marked by progressive muscular weakness and degeneration, with most patients needing a wheelchair by their early teenage years. Patients with DMD will also experience respiratory, cardiac, and cognitive dysfunction as the diseases progresses. The average life expectancy without medical intervention is...

Concentrix Schedules Release of Fiscal First Quarter 2022 Financial Results and Webcast of Investor Conference Call

Written by Customer Service on March 9, 2022. Posted in Public Companies.

NEWARK, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a leading global provider of customer experience (CX) solutions and technology, plans to announce its fiscal first quarter 2022 financial results after market close on Tuesday, March 29, 2022. The Company also plans to host a conference call and webcast with the investment community to discuss the financial results on Wednesday, March 30, 2022, at 9:00 am, Eastern Time. The live conference call will be webcast in listen-only mode in the Investor Relations section of the Concentrix website under “Events and Presentations” at https://ir.concentrix.com/events-and-presentations. A replay will also be available on the website following the conference call. About ConcentrixConcentrix Corporation (Nasdaq: CNXC), is a leading global provider of customer...

Intrado to Divest Flowroute Business

Written by Customer Service on March 9, 2022. Posted in Public Companies.

ISLANDIA, N.Y., March 09, 2022 (GLOBE NEWSWIRE) — Intrado Corporation (“Intrado” or the “Company”), a global leader in technology-enabled services, today announced it has sold the assets of the Flowroute business to BCM One, a leading provider of NextGen Communications and Managed Services for IT leaders and resellers. Flowroute is a cloud-based communications platform that enables communication service providers, value-added resellers, and enterprises to quickly and easily provision and turn up voice and messaging services for cloud-based operators and migrate premise-based communication systems to VoIP. “BCM One and Flowroute have common strategic priorities,” said John Shlonsky, President and Chief Executive Officer of Intrado. “We are pleased that Flowroute customers and employees will have an excellent home at BCM One, and...

Small Pharma to Participate in the 34th Annual Roth Conference

Written by Customer Service on March 9, 2022. Posted in Public Companies.

Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PT LONDON, March 09, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuroscience company focused on psychedelic-assisted therapies for mental health conditions, announces its participation in the 34th Annual Roth Conference, which is being held on March 13-15, 2022, in Dana Point, CA. A fireside chat will be hosted by a banking analyst from Roth in discussion with Small Pharma’s CEO, Peter Rands and Chief Medical and Scientific Officer, Dr. Carol Routledge. Small Pharma will also take part in a panel discussion, Psychedelics: “Immunotherapy” for the Mind. Both will be available by live webcast via the links below and available on the Events and Conferences page of the Company’s website. Details for the fireside...

Lightbridge CEO Seth Grae to Appear Live Tonight on Hannity on Fox News Channel

Written by Customer Service on March 9, 2022. Posted in Public Companies.

RESTON, Va., March 09, 2022 (GLOBE NEWSWIRE) — Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced that Seth Grae, President and CEO of Lightbridge, will be interviewed on FOX News Channel’s “Hannity” show, hosted by Sean Hannity tonight at 9pm ET. Mr. Grae will discuss the ongoing situation in Ukraine, along with America’s energy policy and nuclear power’s increasing role in ensuring energy security. Mr. Grae has made several media appearances, discussing the ongoing situation in Ukraine at the Zaporizhzhia Nuclear Power Plant and Chernobyl, including (with links):Fox Business Network’s “Cavuto: Coast to Coast” hosted by Neil Cavuto on March 4, 2022 Fox Business Network’s “Mornings with Maria” hosted by Maria Bartiromo on March 4, 2022 Fox News Channel’s “Hannity” hosted by Sean Hannity...

Wolters Kluwer to acquire IDS

Written by Customer Service on March 9, 2022. Posted in Mergers And Acquisitions.

Wolters Kluwer to acquire IDS March 9, 2022 — Wolters Kluwer Governance, Risk & Compliance (GRC) has signed an agreement with The Reynolds and Reynolds Company to acquire International Document Services, Inc. (IDS), a leading U.S. provider of compliance and document generation software solutions for the mortgage and real estate industry, for approximately $70 million in cash. IDS will become an integral part of GRC’s Compliance Solutions business, a leading provider of compliance software for U.S. banks, lenders, credit unions, insurers, and securities firms. The acquisition builds on GRC’s existing leadership in digital loan compliance, with end-to-end capabilities spanning from document generation to eClosing, loan analytics and lien solutions. IDS serves over 450 clients, including U.S. mortgage lenders, banks and law firms. The...

Day: March 9, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice